Madrid, September 6, 2016. The Spanish Association of Biosimilars (BioSim) today announced the appointment of Regina Múzquiz as CEO. Múzquiz takes over from Ángel Luis Rodríguez de la Cuerda, one of the main promoters of BioSim, at whose head he has been, provisionally, since its birth while making this position compatible with that of General Director of AESEG, industry employers' association generic pharmaceutical in which it will continue exclusively as of the date.
BioSim's Board of Directors held an extraordinary meeting this morning at the end of which its president, Joaquín Rodrigo, made the appointment public. This is a strategic relay to give continuity to the BioSim project that was born as an AESEG working group, with visibility in the field of biosimilars and dialogue with social agents, and became an independent association with the participation of companies, both biologics and generics, with interests in biosimilar medicines.
Regina Múzquiz will reinforce and consolidate all the strategic areas of BioSim at a national and international level. With a degree in Pharmacy from the Complutense University of Madrid, Múzquiz has previously been director of Institutional Relations at the pharmaceutical companies PharmaMar and Sanofi Aventis, director of Institutional Relations and High Inspection and deputy director general of the Secretariat of the Interterritorial Council of the National Health System in the Ministry of Health.
BioSim, an independent, open and inclusive association
BioSim was officially presented in November 2015 as a totally independent organization from other industry associations and the will to represent all pharmaceutical companies established in Spain that develop, manufacture, market or distribute biosimilar medicines.
There are currently 15 companies that make up BioSim: Accord Biopharmaceuticals, Boehringer Ingelheim, Cinfa Biotech, Gedeon Richter, Kern Pharma, Lilly, mAbxience, Merck, Mylan, Novartis, Rovi, Sandoz, Sanofi, Stada and Teva.